Advising on malaria: Maloff Protect


  • Offering expert advice to customers
  • Malaria Overview
  • Malaria Symptoms
  • Preventing Malaria
  • Know Your Customers
  • Selecting the right chemoprophylaxis
  • Recommending Maloff Protect
  • Customer learning scenario
  • Bringing a sale of Maloff Protect to life
  • Bite prevention
  • Additional travel advice
  • Resources and references
  • Assessment questions
  • Action & Evaluation

Maloff Protect LogoAtovaquone/proguanil

Advising on malariaOffering expert advice to customers

There is a range of effective anti-malarial products available from the pharmacy, including Pharmacy-only products such as Maloff Protect. This module will show how your advice can make all the difference to customers, helping you to sell Maloff Protect, which is available without prescription, to appropriate travellers.


After completing this module you will understand:

  • The significance of malaria worldwide and symptoms
  • The four key elements of malaria prevention
  • The different types of travellers who require malaria prophylaxis
  • When to recommend Maloff Protect
  • The additional travel health selling opportunities for your pharmacy
Content developed by CIG Healthcare Partnership working with Glenmark Pharmaceuticals
glenmark logo
Product information

Presentation: atovaquone 250mg, proguanil 100mg. Indication(s): Chemoprophylaxis of Plasmodium falciparum (P. falciparum) malaria in adults. Check official guidelines (e.g. World Health Organisation (WHO) and public health authorities' guidelines) before dispensing. Dosage: One tablet daily with food or a milky drink at the same time each day. Commence 1-2 days prior to entering malaria-endemic area, continue for the duration of the stay plus seven days after leaving the area. The maximum duration of travel for which Maloff Protect can be supplied without prescription is 12 weeks (93 tablets). For longer durations of travel, advice should be sought from a doctor or other qualified prescriber. Contraindications, precautions, side effects: Contraindications: hypersensitivity to atovaquone, proguanil or excipients, renal disease, hepatic impairment, children and adolescents. Precautions: if vomiting occurs within one hour of dosing repeat dose. If allergic reaction develops, discontinue use promptly and seek medical treatment. Refer the following patients to a doctor or other qualified prescriber: those taking etoposide, rifampicin, rifabutin, metoclopramide, warfarin and other anticoagulants, tetracycline, indinavir, efavirenz, zidovudine, boosted protease inhibitors, those with a history of depression or seizures, those with TB, patients who are pregnant, planning to become pregnant or those breast feeding. Safety and effectiveness has not been established in patients <40kg. Remind travellers of the need for a full travel consultation. The most common side effects are headache, abdominal pain and diarrhoea. Other important reactions reported are severe allergic reactions, pancytopenia in patients with severe renal impairment, severe skin reactions, seizure, hallucinations, liver inflammation, depression. Legal category: P. PL Holder: Glenmark Pharmaceuticals Europe Limited, Laxmi House, 2 B Draycott Avenue, Kenton, Middlesex, HA3 0BU. PL number: 25258/0166 RRP (excluding VAT): 24 Tablet Pack £39.00; 36 Tablet Pack £58.50 Date of preparation: 13 February 2018

Adverse events should be reported. Reporting forms and information can be found at

Originally Published by Pharmacy Magazine